title: The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
abstract: BACKGROUND
  Galectin-3 is a new biomarker involved in inflammation and fibrogenesis and could therefore contribute to myocardial remodeling. We examined the prognostic value of baseline galectin-3 in a substudy involving approximately 30% of participants in the CORONA study.
  
  
  METHODS
  Patients (n = 1462) aged >60 years with systolic, ischemic heart failure (HF) were randomized to 10 mg/d rosuvastatin or placebo. The primary composite end point was cardiovascular death, nonfatal myocardial infarction, or stroke (n = 408).
  
  
  RESULTS
  In the unadjusted analysis, galectin-3 was associated with all end points considered, except hospitalization for worsening of HF. In multivariable analyses, adjusting for other clinical and biochemical predictor variables, galectin-3 was significantly associated with the primary end point (hazard ratio [HR] 1.53 [1.10-2.12], P = .011) as well as all-cause (HR 1.61 [1.20-2.29], P = .002) and cardiovascular mortality (HR 1.70 [1.19-2.42], P = .003), sudden death (HR 1.83 [1.14-2.94], P = .012), and the coronary end point (HR 1.48 [1.03-2.12], P = .035). However, when N-terminal pro-brain natriuretic peptide was added to the model, galectin-3 association with the end points was markedly attenuated and no longer significant.
  
  
  CONCLUSIONS
  Galectin-3 is not associated with outcome in older patients with advanced chronic systolic HF of ischemic etiology when adjusting for N-terminal pro-brain natriuretic peptide and may therefore have limited use in the prognostication of elderly patients with systolic HF in clinical practice.
authors.affiliation: Deparment of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. lars.gullestad@medisin.uio.no
authors.forename: Lars
authors.initials: L
authors.lastname: Gullestad
authors.forename: Thor
authors.initials: T
authors.lastname: Ueland
authors.forename: John
authors.initials: J
authors.lastname: Kjekshus
authors.forename: Ståle H
authors.initials: SH
authors.lastname: Nymo
authors.forename: Johannes
authors.initials: J
authors.lastname: Hulthe
authors.forename: Pieter
authors.initials: P
authors.lastname: Muntendam
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
authors.forename: John
authors.initials: J
authors.lastname: Wikstrand
authors.forename: Pål
authors.initials: P
authors.lastname: Aukrust
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D037502:Galectin 3 / Q000097:blood*; D054143:Heart Failure, Systolic / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D020521:Stroke / Q000401:mortality; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D005464:Fluorobenzenes; D037502:Galectin 3; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium